Table 2. Postinfusion clinical,... | American Society of Hematology

Table 2.

Postinfusion clinical, radiographic, and treatment data

Variable	Patient 1	Patient 2	Patient 3	Patient 4	Patient 5
Age at infusion, y	7	14	13	2.5	7
CART product	CART22-65s	CART22-65s	huCART19	Tisacel	Investigational CTL019
Acute clinical course
Limb weakness onset day after infusion	D22	D25	D5-D10	D15	D36
Pertinent MRI brain findings	↑T2/FLAIR and restricted diffusion (nonenhancing) in bilateral deep cerebral white matter (D24)	↑T2/FLAIR and restricted diffusion (nonenhancing) in subcortical, deep, and periventricular cerebral white matter (D25)	↑T2/FLAIR (nonenhancing, no restricted diffusion) in supratentorial white matter and brainstem (D10)	↑T2/FLAIR (nonenhancing, no restricted diffusion) in the cerebral white matter (D15)	↑T2/FLAIR in corona radiata, centrum semiovale, corpus callosum, and periventricular white matter (D39)
Pertinent MRI spine findings	↑T2 in central and midline posterior cord, with slight edema in anterior midline cervical cord (D26)	↑T2 (nonenhancing) in dorsal columns of the cord (D25)	↑T2 (nonenhancing) and mild expansion in central portion of the entire cord (D10)	Extensive, patchy, nonenhancing multifocal T2 lesions, some expansile (D16)	Normal
Day of death	D31	D30	—	D189	D72
Pertinent autopsy findings	Spinal cord: White matter pallor throughout the cord, few macrophages, extremely rare T lymphocytes, absent B lymphocytes	—	—	—	Spinal cord: normal Brain: cerebral cortex white matter pallor, with vacuolation and gliosis, axonal swelling
Concomitant CRS and CRS and ICANS therapies received
Maximum CRS	Grade 2	Grade 2	Grade 4	Grade 1	Grade 4
Tocilizumab	Yes	Yes	Yes	No	Yes
Corticosteroids	Yes	Yes	Yes	Yes	Yes
Plasmapheresis	No	No	Yes	Yes	No
IVIG	No	No	Yes	Yes	Yes
Sinemet	Yes	No	Yes	Yes	Yes
Anakinra	No	Yes	Yes	No	No
Other anticytokine therapy	No	No	No	No	No

Variable	Patient 1	Patient 2	Patient 3	Patient 4	Patient 5
Age at infusion, y	7	14	13	2.5	7
CART product	CART22-65s	CART22-65s	huCART19	Tisacel	Investigational CTL019
Acute clinical course
Limb weakness onset day after infusion	D22	D25	D5-D10	D15	D36
Pertinent MRI brain findings	↑T2/FLAIR and restricted diffusion (nonenhancing) in bilateral deep cerebral white matter (D24)	↑T2/FLAIR and restricted diffusion (nonenhancing) in subcortical, deep, and periventricular cerebral white matter (D25)	↑T2/FLAIR (nonenhancing, no restricted diffusion) in supratentorial white matter and brainstem (D10)	↑T2/FLAIR (nonenhancing, no restricted diffusion) in the cerebral white matter (D15)	↑T2/FLAIR in corona radiata, centrum semiovale, corpus callosum, and periventricular white matter (D39)
Pertinent MRI spine findings	↑T2 in central and midline posterior cord, with slight edema in anterior midline cervical cord (D26)	↑T2 (nonenhancing) in dorsal columns of the cord (D25)	↑T2 (nonenhancing) and mild expansion in central portion of the entire cord (D10)	Extensive, patchy, nonenhancing multifocal T2 lesions, some expansile (D16)	Normal
Day of death	D31	D30	—	D189	D72
Pertinent autopsy findings	Spinal cord: White matter pallor throughout the cord, few macrophages, extremely rare T lymphocytes, absent B lymphocytes	—	—	—	Spinal cord: normal Brain: cerebral cortex white matter pallor, with vacuolation and gliosis, axonal swelling
Concomitant CRS and CRS and ICANS therapies received
Maximum CRS	Grade 2	Grade 2	Grade 4	Grade 1	Grade 4
Tocilizumab	Yes	Yes	Yes	No	Yes
Corticosteroids	Yes	Yes	Yes	Yes	Yes
Plasmapheresis	No	No	Yes	Yes	No
IVIG	No	No	Yes	Yes	Yes
Sinemet	Yes	No	Yes	Yes	Yes
Anakinra	No	Yes	Yes	No	No
Other anticytokine therapy	No	No	No	No	No

Dashes denote not applicable (patient 3 did not die; no autopsy findings available on patients 2, 3 or 4). IVIG, intravenous immunoglobulin.